M.Carmen Vidal Carou1, Mariluz latorre2, Teresa Veciana3, Oriol Comas4, Jaume Bori5.
1,2,3,4 Nutrition, Food Sciences and Gastronomy Department – XaRTA – INSA, University of Barcelona, Food and Nutrition Torribera Campus
5 Diamine Oxidase R+D+i Plant URV-Sescelades Campus
2017-2019 // Dietary management with Diamine Oxidase (DAO) in patients with non-allergic rhinitis: a randomized, controlled, double-blind clinical trial to test efficacy and safety.
1.Mayo1, GN. Esquía1, MJ. Rial2
Complexo Hospitalario Universitario A Coruña (CHUAC).
Download the paper clicking here
Abstract: Lactose intolerance (LIT) is one of the major causes of irritable bowel syndrome (IBS) spectrum complaints. Differences in inadequate lactose digestion are described as various LIT phenotypes with basically unknown pathophysiology. In LIT patients, we retrospectively assessed the effect of histamine intolerance (HIT) on expiratory hydrogen (H2) during H2 lactose breath tests. In a retrospective evaluation of charts from 402 LIT patients, 200 patients were identified as having only LIT. The other 202 LIT patients were found to additionally have diamine oxidase (DAO) values of <10 U/mL, which indicates histamine intolerance (HIT). To identify HIT, standardized questionnaires, low serum DAO values and responses to a histamine-reduced diet were used. Patients were separated into three diagnostic groups according to the result of H2 breath tests: (1) LIT, with an H2 increase of >20 parts per million (ppm), but a blood glucose (BG) increase of >20 mg/dL, (2) LIT with an H2 increase of 20 ppm in combination with a BG increase of <20 mg/dL, and (3) LIT with an exhaled H2 increase of <20 ppm and BG increase of <20 mg/dL. Pairwise comparison with the KruskalWallis test was used to compare the areas under the curve (AUC) of LIT and LIT with HIT patients. Exhaled H2 values were significantly higher in H2 > 20 ppm and BG < 20 mg/dL patients with LIT and HIT (p = 0.007). This diagnostic group also showed a significant higher number of patients (p = 0.012) and a significant higher number of patients with gastrointestinal (GI) symptoms during H2 breath tests (p < 0.001). Therefore, low serum DAO values, indicating HIT, influence results of lactose tolerance breath tests.
Citation: Schnedl,W.J.; Meier-Allard, N.; Michaelis, S.; Lackner, S.; Enko, D.; Mangge, H.; Holasek, S.J. Serum Diamine Oxidase Values, Indicating Histamine Intolerance, Influence Lactose Tolerance Breath Test Results. Nutrients 2022, 14, 2026. https://doi.org/10.3390/nu14102026
Wolfgang J. Schnedl 1,* , Nathalie Meier-Allard 2, Simon Michaelis 3 , Sonja Lackner 2 , Dietmar Enko 3,4 , Harald Mangge 4 and Sandra J. Holasek 2
1 Practice for General Internal Medicine, Dr. Theodor Körnerstrasse 19b, 8600 Bruck an der Mur, Austria
2 Division of Immunology and Pathophysiology, Otto Loewi Research Center, Medical University of Graz, Heinrichstrasse 31a, 8010 Graz, Austria; email@example.com (N.M.-A.); firstname.lastname@example.org (S.L.); email@example.com (S.J.H.)
3 Institute of Clinical Chemistry, Laboratory Medicine, Hospital Hochsteiermark, Vordernberger Straße 42, 8700 Leoben, Austria; firstname.lastname@example.org (S.M.); email@example.com (D.E.)
4 Clinical Institute of Medical, Chemical Laboratory Diagnosis, Medical University of Graz, Auenbruggerplatz 30, 8036 Graz, Austria; firstname.lastname@example.org
- Correspondence: email@example.com; Tel.: +43-3612-55833; Fax: +43-3612-55833-22
In February 2022, the active ingredient diamine oxidase – or DAO – produced by AB Biotek’s DR Healthcare division, as well as the solutions derived from it, have obtained the GRAS (Generally Recognized As Safe, per sections 201(s) and 409 of the U.S. Food & Drug Act) qualification from the U.S. Food & Drug Administration. This allows for the upcoming launch in the U.S. marketplace.
From the FDA regulations 21 CFR 170.3 and 21 CFR 170.30, the use of a food substance may be GRAS through scientific procedures and scientific evidence and is based on in published studies.
Additionally, at the same time, the Directorate-General for Hygiene, Food Safety & Nutrition in Rome, Italy, and the Ministry of Finance, Economy & Recovery in Paris, France, both approved the launch of DAO products in those two countries.
These three steps represent new support for continued international expansion of DR Healthcare’s solution portfolio targeting consumers with DAO deficiency.
DAO – an enzyme naturally secreted by the human body – is frequently used as a nutritional supplement to treat disorders from histamine accumulation including migraines, fibromyalgia, irritable bowel syndrome (IBS), atopic skin or even attention deficit hyperactivity disorder (ADHD). Approximately 15 percent of the population suffers from a DAO deficiency, both genetic and acquired.
About DR Healthcare
Founded in Barcelona, Spain, in 2007, DR Healthcare is a biomedical company specialized in medical nutrition and dedicated to the research, development, innovation, marketing and licensing of new nutraceuticals, functional foods, active ingredients and customized solutions. Our medical nutrition products are aimed at dietary management of chronic diseases, physiological dysfunctions and/or metabolic diseases, mainly associated with metabolic disorders caused by a deficiency of the intestinal enzyme diamine oxidase (DAO). DR Healthcare also produces DAO for both human and animal use and offers proprietary solutions for the food, veterinary and animal health industries. More information is available at www.dr-healthcare.com/en.
About AB Biotek
AB Biotek contributes to the success of customers through the delivery of customized fermentation-based, sustainable solutions containing proprietary and/or purposefully sourced microorganisms to created differentiated food, beverage, health & nutrition business opportunities. Science and advanced microorganism fermentation technology are core enablers. AB Biotek has commercial scale production and research development facilities located around the world. For more information about our product applications and unmatched technical service capabilities, please visit www.abbiotek.com.
You are invited to map a new future in managing DAO Deficiency attending the International Congress on DAO Deficiency.
SAVE THE DATE: November 4th 2021
At DR HEALTHCARE, we are pioneers in DAO Deficiency. Since our beginnings, scientific evidence and research have driven each one of our steps. The time has come to share this knowledge with the scientific and medical community, nutrition specialists, and patients who suffer from this metabolic deficiency’s different recurring symptoms.
Together, we can go farther.
Which is why we are delighted to invite you to the International Congress of DAO Deficiency, to be held 4 November 2021, in virtual format.
Our end goal:
is to reinforce knowledge of DAO Deficiency through a complete programme of scientific sessions, with experts of worldwide renown. With a forward-looking approach, we will address both diagnosis and treatment, as well as how knowledge of DAO Deficiency has led to a paradigm shift in the field of medical nutrition.
The event will be held entirely online:
as required by this exceptional situation caused by the pandemic. However, this way we will also be able to make our shared knowledge and experiences available to professionals all around the world, saving on costs and travel, and reducing our ecological footprint.
Technology will make it possible:
for guests to attend all conferences through an immersive, comprehensive experience. In addition to the extensive medical and scientific programme, the exhibition with 3D stands, and online interaction with guests, congress participants and speakers will provide a one-of-a-kind stage with services just like at a face-to-face event. All in real time.
We eagerly await you.
Gerald Dard Juanjo Duelo
Managing Director ABBiotek Global Business Development Director Enzymes
Article published in bakeryandsnacks.com the 29-oct-2021, by Gill Hyslop. Publication link
The business unit of AB Biotek – which is part of the global yeast and bakery ingredients specialist – is hosting the first International Congress of DAO Deficiency online on 4 November.
Respective leaders in fermentation science and DAO-based medical nutrition join together to focus on innovative enzyme-based solutions for the human nutrition & health market.
Puedes decargar el suplemento en pdf clicando sobre la imagen de abajo o a través de aquí.
el farmacéutico.es publica su suplemento nº 585 titulado “Migraña y déficit de DAO (Diamino Oxidasa)”.
En esta publicación se exponen las bases científicas y clínicas de la migraña causada por déficit de DAO y se muestran los métodos diagnósticos y las formas de manejo de la migraña causada por esta alteración metabólica. También se muestran los productos que se pueden encontrar en farmacias para el manejo y diagnóstico de la migraña causada por déficit de DAO.
El suplemento ha sido elaborado por los PhD. Medical Writer Antoni X. Torres-Collado y Eva Morán-Salvador, editado por ediciones MAYO y publicado el 2 de marzo – 2020.
Contenidos del suplemento nº585 “Migraña y déficit de DAO (Diamino Oxidasa)”:
- ¿Qué es la migraña?
- Sintomatología y diagnóstico
- Manejo y tratamiento de la migraña
- ¿Qué sucede en la migraña?
- Fases de la crisis de migraña
- Mecanismos fisopatológicos
- What is histamine?
- ¿Qué es la Diamino Oxidasa?
- Déficit de DAO y migraña
- embarazo y migraña
- síntomas asociados (comorbilidad de la migraña)
- Tratamiento de la migraña por déficit de DAO
- ¿Cómo manejar la migraña por déficit de DAO desde la farmacia?
- Suplementación con DAO en el paciente con migraña: alimentos para usos médicos especiales
The past 20 May was published in the European Journal of Neurology an article in which the doctors Wolfgang J Schnedl and Robert Queissner stated that there was apparently a greater relationship between the cause of migraines and histamine rather than with ethanol present in alcoholic beverages.
In the letter to the editor that have published both doctors, reflect on another recent publication of Onderwater et al, in the same magazine, in which it is intended to show by epidemiological studies a causal relationship between ethanol of alcoholic beverages and the development of migraines in people who consume.
However, both doctors argue that no one has been identified as specific pathophysiologic mechanism that correlate the alcohol intake with migraines and headaches (being the red wine the alcoholic beverage that has been related in the study population of Onderwater et al with migraine).
They argue, in contrast, that greater evidence exists so far as a cause of migraines and headaches are the deficit of the enzyme diamine oxidase (DAO) (alteration in the main route of metabolism of dietary histamine and can be present as a heritable genetic alteration) and the effects that generate exogenous histamine and other biogenic amines (such as tyramine, phenylethylamine, putrescine, cadaverine, spermidine, serotonin, tryptamine, agmatin) when they accumulate in plasma after being ingested.
The results of measurement of these amines into alcoholic beverages show that has been quantified higher concentrations in red wine (with concentrations >2,200 μg/L), being double the concentration that can be found in the white wine ( ~900 μg/L), and much higher even than in distilled spirits such as vozka. This difference in concentration also has been related to a lower incidence of migraine in studies in which the population consumed vozka than in the population that consumed wine.
With regard to the pathophysiologic mechanism of the cause of migraines by DAO deficiency, certain genotypes of the enzyme DAO and its allelic variants (all of them involved in a deficit of the enzyme activity) have shown association with increased risk of migraine. On the other hand, recent studies consisting of double-blind randomized trials in which a population of migraine patients were treated with supplements of DAO, have shown a reduction in the number, frequency, and intensity of migraines. States of these results, other studies of supplementation with DAO on patient population with intolerance to histamine (HIT), has shown a reduction of headaches and the rest of the symptoms related to this pathology.
Outside the interest and data and studies shown about people affected with a diagnosis of DAO deficiency and intolerance to histamine, this letter to the editor does not mention the inhibitory role of ethanol on the activity of the diamine oxidase, which explains the syndrome of the hangover after the acute intake of alcohol in people without a diagnosis of HIT or DAO deficiency.
Dr. Wolfgang J Schnedl is professor of internal medicine and doctor in the General Internal Medicine Practice Theodor Könerstrasse (Austria), and Dr. Robert Queissner is a professor in the Department of Psychiatry and Psychotherapeutic Medicine of the Medical University of Graz (Austria).
The biomedical company DR Healthcare installs a research center and production plant on the Campus of Rovira i Virgili University – Indicador d’Economia
The center will dedicate 75% of the activity in research and a 25% in the production of the enzyme DiAmine Oxidase (DAO) as an ingredient in functional foods
DR Healthcare has invested 500,000 euros in this new center for research and in the production plant, both located in the Sescelades Campus of the URV (Tarragona, Spain). This biomedical company manufactured in Tarragona the enzyme that is the essential ingredient of its innovative product indicated for the dietary treatment of migraine.“The URV is a dynamic university and in Tarragona we hope to generate many synergies with different research groups located in the same campus” explains Juanjo Duelo, founder and CEO of DR Healthcare.
DR Healthcare was founded 12 years ago as a emergent company (start up) of the Universitat de Barcelona to investigate the relationship between diet and migraine. In 2010 published one of the first studies, which demonstrated the relationship between the DAO deficiency and the triggering of migraine. In these years the company, with headquarters in Barcelona, has focused the activity to generate scientific and clinical evidence about the deficit of diaminooxidase, the key enzyme in the metabolism of histamine. This deficiency leads to a series of associated disorders that, in addition to migraine, include fibromyalgia, dermatological problems, rhinitis, irritable bowel syndrome or Attention Deficiency- Hyperactivity Disorder (ADHD).
The dietary product of DR Healthcare for the treatment of migraine obtained last year the official certificate of the European Union that categorizes it as “new food with therapeutic objective.” This new recognition should definitely boost the marketing of the DAO enzyme as “food for special medical purposes,” according to Duelo, beyond the 500 pharmacies in within the Spanish state that they have participated in a pilot test.
The goal of the new plant of DR Healthcare
The company has generated more than 80 patents and the aim of the Tarragona plant is to continue with the production of DAO of animal origin for marketing, in addition to do research to lead to other modalities of this enzyme, such as that of plant and biotechnology origin. “We are the only company specialized in DAO deficiency and in the treatment of its associated symptoms, and we want that the plant of Tarragona to become a center of reference from where we will promote various research projects in collaboration with other departments of the University,” explains Juanjo Duelo, founder and director of the company.The plant has been installed in the building N5 of the Sescelades Campus and will be managed by Jaume Bori, holds a bachelor’s degree in Biochemistry and Biotechnology by the URV and PHD in Environmental Engineering. His figure will depend on the scientific department of the company, and will be devoted to seek synergies in the environment of the URV and launch projects with different areas of the University.The incorporation of this new company in the campus is in the line of the University, who wants to promote the relationship with the company and to promote the transfer of knowledge for the benefit of society.
Other arguments in favor of this location, according to Duelo is that “we are looking for partners to be able to expand all over the world. If we have to use the airport of Tarragona or the Prat, we will obtain the same as if we are in Barcelona.”
Objective of the URV: The attraction of companies of high technological value
The attraction of companies of high technological value is a strategic objective for the URV, who currently maintains advanced negotiations with another company in the health sector. “This type of companies are very interesting because with their level of specialization cause interaction, mutual learning and generate new opportunities and projects. Contribute to raise the bar of the research that we do in the university,” explains Lourdes Jane, director of the Center for Transfer of Technology of the Foundation URV.
Data of interest
The Technology Transfer Center of the Foundation URV managed 318 collaboration contracts with companies and institutions the year 2018. Transfer contracts allow to create applicable solutions, and from the research results that are generated in the university. Of the 190 clients with whom collaborated the URV last year, 85 are private companies. The rest are public entities, associations, foundations and cooperatives. The sum of the value of contracts was supposed to the university 5.6 million euros of income.
Access the original new through here.